drugset / Trial / NCT00367016
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of this study is to look at measures that will help scientists understand the way Omalizumab, an FDA-approved anti-allergy medication, works.
Timeline
- Start
- 2004-02
- Primary completion
- 2012-10-17
- Completion
- 2012-10-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omalizumab | Monoclonal antibody | — | Subcutaneous |